Introduction {#s1}
============

The novel coronavirus, COVID-19, has taken the world by storm, causing widespread quarantines and lockdowns of entire nations, actions not seen in over a century since the 1918 Spanish Influenza. The natural defense against an infectious pathogen is to avoid contracting the pathogen altogether through quarantine, a practice employed since antiquity ([@B1]). As world leaders allude to the promise of vaccines in a brief time period and the development of novel agents for treatment, perhaps we should examine whether already existing therapeutics are effective in treating people affected with COVID-19.

Supportive Evidence for Hydroxychloroquine {#s2}
==========================================

Researchers in China, the nation first affected by COVID-19, expeditiously assessed the potential use of already existing compounds in treating COVID-19. Hydroxychloroquine and chloroquine (non-hydroxylated compound) have demonstrated effective control of infection with COVID-19 *in vitro* ([@B2]). Hydroxychloroquine demonstrated comparable efficacy to chloroquine when used as a treatment against SARS-CoV-2 infection *in vitro* and in Vero cells and was superior to chloroquine when used as pre-treatment prophylaxis ([@B3]). Impressive *in vitro* results conducted and published in rapid timeframes have sparked interest into the use of these compounds in the fight against COVID-19 infection, igniting a wave of international clinical trials and leading to the adoption of hydroxychloroquine and chloroquine into national guidelines in several countries, including China, Korea, and Poland, for the treatment of COVID-19 ([@B4]).

The potential use of chloroquine or hydroxychloroquine as an antiviral is not a novel concept. Chloroquine has demonstrated efficacy against SARS-CoV *in vitro*, against avian influenza A H5N1 in mice, and against human coronavirus OC43 in newborn mice ([@B5]--[@B7]), demonstrated long before the emergence of the novel SARS-CoV-2. Although hydroxychloroquine and chloroquine have demonstrated therapeutic antiviral potential in these models, the efficacy of these compounds as antivirals in large controlled clinical studies in humans has yet to be demonstrated.

Clinical evidence is now mounting, as evidenced in a recent clinical study in February 2020 where Gao and colleagues published an interim report from clinical trials describing that chloroquine has demonstrated superior efficacy in the treatment of COVID-19 infection, as seen in multiple disease parameters in humans, leading to a recommendation of its widespread use ([@B8]). This report noted significant improvements of chloroquine improving disease parameters including time to seronegative conversion and shortening of disease, though the magnitude of these effects has yet to be published. A clinical trial recently published from Marseille found hydroxychloroquine to be superior to standard of care in eradication of the virus ([@B9]). This study had limitations including a small size, a lack of reporting of clinical assessments, and open-label enrollment ([@B9]). The results remain promising and are consistent with previous research. These studies are complemented by recent additional reports of encouraging results with hydroxychloroquine or chloroquine in news outlets.

Discussion {#s3}
==========

Given that hydroxychloroquine and chloroquine are among the most widely prescribed medications in the world, we can be generally confident about their safety. Of course, with any therapeutic agent there are always risks of adverse effects, and thus the risks and benefits of treatment as always need to be determined on an individual basis. Risks of treatment with hydroxychloroquine include retinal damage (associated with long term use) and QT prolongation. Hydroxychloroquine is contraindicated in people with a history of hypersensitivity to 4-aminoquinoline compounds and should be used with caution in people with glucose-6-phosphate dehydrogenase deficiency ([@B10]). Recommended dosing regimens from recent literature, national guidelines, and individual hospital guidelines for COVID-19 have been similar to those currently used for malaria ([@B3], [@B8]). Given that hydroxychloroquine has demonstrated superior efficacy *in vitro* for the prevention of infection, it should be considered as a first-line agent against COVID-19 infection over chloroquine. Hydroxychloroquine should be utilized given the low risks associated with treatment and be further explored as a therapeutic agent at a dose of 400 mg orally per day. In addition to larger clinical studies to evaluate therapeutic efficacy in the setting of active infection, of particular interest would be further studies examining the utility of hydroxychloroquine for prophylaxis against COVID-19 at a weekly dose of 400 mg orally given the long half-life (over 40 days), its previous utility as a prophylactic agent against malaria infections, and promising *in vitro* results ([@B3], [@B11]). Despite limited clinical data, Hydroxychloroquine taken at 400 mg orally per day during active infection may offer an avenue of infection control and treatment of affected individuals in a time of rapid need for therapeutic options. Perhaps the answer to this once in a lifetime pandemic can be found from a dependable agent that has been used in the treatment of malaria for several decades and can be found readily throughout the world.
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